Market Scenario
Xanthoma are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Xanthoma appear as well-differentiated, and firm overgrowths of fibrous tissue. According to the U.S National Library of Medicine, Xanthoma are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000 people worldwide. It is also stated that nearly 900 to 1,500 new cases are registered per year in the United States. Tumors associated with familial adenomatous polyposis (FAP) are less common than sporadic Xanthoma.
On molecular level, desmoid tumor is characterized by one of the two mutations in the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is detected, especially, when pathological differential diagnosis is difficult.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4859

According to the Desmoid Rare Foundation, individuals within the age group of 15 and 60 are more likely to get affected by this condition. It is also stated that the condition is more prevalent in women than in men (2:1).
For the diagnosis of desmoid tumor there are many non-invasive methods available to detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The actual diagnosis of this tumor can be made only after examining a small piece of the tumor by a trained pathologist.
The symptoms of Xanthoma include a painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by compressed nerves or muscles, and others.
The most commonly used treatment options for Xanthoma are anti-inflammatory medication, Chemotherapy, Hormone therapy, and surgery among others. Various new therapies are under investigation such as Angiogenesis inhibitors, and Chemotherapy agents. As mutations in the CTNNB1 gene is found to be most commonly occurring in desmoid tumor. So, it is expected that very soon mutation analysis be used to predict the risk of recurrence and to aid in designing individual therapies.
Notably, the market is expected to expand in the near future due to rising demand of effective chemotherapeutic agents, high unmet needs of current treatment, and increase in research and development expenditure.
Despite these drivers, there are some issues associated with Xanthoma market. High cost of treatment & management of Xanthoma and related disorders, and lack of infrastructure in the middle and low income countries may hamper the growth of the market.
It is estimated that Xanthoma market is expected to grow at a CAGR 4.5% during the forecast period of 2017-2023.
Segmentation
The Xanthoma market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, others
On the basis of treatment, market is classified into surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, others. Novel molecular-targeted therapy is further segmented into gleevec based therapy, and sorafenib based therapy
On the basis of end-user, market is segmented into hospital, clinics, and others.
Regional Analysis
The Americas dominate the Xanthoma market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.
Europe holds the second position in the Xanthoma market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing Xanthoma market owing to the huge patient pool and developing healthcare technology.
The Middle East & Africa has the lowest market for Xanthoma market due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4860
Detailed Table of Contents:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
...Continued

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4859
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]